Pomalyst® (pomalidomide) is an immunomodulatory drug that is used only for patients with relapsed and refractory myeloma who have received at least two prior therapies, including Revlimid® (lenalidomide) and Velcade® (bortezomib), and have demonstrated disease progression on or within 60 days of completion of the last therapy.